Hayama Noriko, Ihara Hiroaki, Honma Yuichirou, Itoigawa Yukinari, Kaira Kyoichi, Fujii Mitsuhiro
Department of Respiratory Medicine Koto Hospital Tokyo Japan.
Department of Respiratory Medicine Comprehensive Cancer Center, International Medical Center, Saitama Medical University Saitama Japan.
Respirol Case Rep. 2020 Jul 30;8(7):e00636. doi: 10.1002/rcr2.636. eCollection 2020 Oct.
Immune checkpoint inhibitors (ICIs) are known to induce gastrointestinal adverse events. Colitis occurs most frequently, and gastritis is less common. A few case reports of gastritis induced by ICIs have indicated that colitis induced by cytotoxic T-lymphocyte antigen-4 (CTLA-4) resembles inflammatory bowel disease (IBD) and that programmed death-1/programmed death ligand-1 (PD-1/PD-L1) inhibitor can also induce the same type of colitis. We herein encountered a case of gastritis arising after 25 cycles of pembrolizumab administration in which the pathological and endoscopic findings resembled those of IBD. ICIs may induce gastritis in a manner similar to the pathogenesis of IBD.
免疫检查点抑制剂（ICIs）已知会诱发胃肠道不良事件。结肠炎最为常见，胃炎则较少见。一些关于ICIs诱发胃炎的病例报告表明，细胞毒性T淋巴细胞抗原4（CTLA-4）诱发的结肠炎类似于炎症性肠病（IBD），程序性死亡受体1/程序性死亡配体1（PD-1/PD-L1）抑制剂也可诱发相同类型的结肠炎。我们在此遇到一例在接受25个周期帕博利珠单抗治疗后出现的胃炎病例，其病理和内镜检查结果与IBD相似。ICIs可能以类似于IBD发病机制的方式诱发胃炎。
